UltraGreen.ai Limited said on Aug, 24 2026 that it remains confident in its long-term strategy and competitive position after recent regulatory approvals for new competitors in the United States indocyanine green market.

Chief Executive Officer Ravinder Sajwan told shareholders the company has operated in fluorescence-guided surgery for more than a decade and has built its market standing through surgeon relationships, clinical research support and a strong manufacturing record.

While acknowledging that new entrants have secured US Food and Drug Administration clearance, the CEO noted that approval does not guarantee commercial launch or rapid adoption. UltraGreen.ai will adjust its commercial approach once competitors’ pricing, distribution and customer strategies become clear, he said.

The company outlined plans to expand beyond indocyanine green through a platform that integrates dye, imaging and software. Its PerfusionWorks product has completed European Medical Device Regulation conformity assessment and is awaiting formal CE certification, after which UltraGreen.ai intends to seek FDA clearance.

UltraGreen.ai’s regulatory footprint now covers more than 43 countries across Europe, the Middle East and Asia, and the firm reported continued growth outside its established US business.

Sajwan added that he has been buying UltraGreen.ai shares and plans to increase his personal stake, stating the purchases reflect confidence in the company’s prospects.

The board said it will keep monitoring market developments and update shareholders on any material changes.